Medtronic (NYSE:MDT) Rating Increased to Buy at Wall Street Zen

Wall Street Zen upgraded shares of Medtronic (NYSE:MDT) from a hold rating to a buy rating in a report released on Saturday morning.

A number of other research firms have also weighed in on MDT. Royal Bank Of Canada increased their target price on Medtronic from $111.00 to $118.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 19th. Robert W. Baird set a $103.00 price target on shares of Medtronic in a research note on Tuesday. Morgan Stanley lifted their price objective on shares of Medtronic from $107.00 to $117.00 and gave the company an “overweight” rating in a report on Wednesday, November 19th. Daiwa Capital Markets upped their target price on shares of Medtronic from $104.00 to $117.00 and gave the stock a “buy” rating in a research note on Tuesday, November 25th. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of Medtronic in a research report on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and twelve have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $109.94.

Medtronic Price Performance

MDT stock opened at $98.63 on Friday. The stock has a market cap of $126.45 billion, a PE ratio of 26.59, a P/E/G ratio of 2.60 and a beta of 0.71. Medtronic has a 12 month low of $79.29 and a 12 month high of $106.33. The company has a 50-day moving average price of $97.38 and a 200 day moving average price of $93.41. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.31 by $0.05. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The business had revenue of $8.96 billion during the quarter, compared to the consensus estimate of $8.86 billion. During the same quarter last year, the firm earned $1.26 earnings per share. The firm’s quarterly revenue was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities research analysts anticipate that Medtronic will post 5.46 earnings per share for the current year.

Medtronic Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 16th. Stockholders of record on Friday, December 26th will be given a $0.71 dividend. This represents a $2.84 annualized dividend and a dividend yield of 2.9%. The ex-dividend date of this dividend is Friday, December 26th. Medtronic’s dividend payout ratio is presently 76.55%.

Hedge Funds Weigh In On Medtronic

Several institutional investors have recently bought and sold shares of MDT. 1248 Management LLC bought a new stake in Medtronic during the 1st quarter valued at $26,000. Delos Wealth Advisors LLC bought a new stake in Medtronic during the second quarter valued at about $27,000. Corundum Trust Company INC bought a new stake in Medtronic during the third quarter valued at about $27,000. Twin Tree Management LP purchased a new position in Medtronic in the first quarter valued at about $29,000. Finally, Valley Wealth Managers Inc. bought a new position in Medtronic in the third quarter worth about $29,000. 82.06% of the stock is owned by hedge funds and other institutional investors.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic filed an S-1 to take its Diabetes unit, MiniMed, public — the preferred separation path is an IPO followed by a split-off. Management says the move is part of a planned separation aimed at creating two focused companies, which could unlock value and provide strategic clarity. Medtronic announces filing of IPO registration statement for Diabetes business, MiniMed
• Positive Sentiment: Regulatory and product progress: Medtronic (and peers) secured FDA nods for liquid embolic systems — a reminder the company continues to advance therapeutic devices that can support organic growth beyond the diabetes separation. Medtronic, J&J MedTech both get FDA nods for liquid embolic systems
• Neutral Sentiment: Ownership and structure details may limit immediate financial impact — media reports note Medtronic expects to retain majority voting control (reported at least ~80.1% of voting stock), suggesting the IPO could be more about strategic focus and value crystallization than a full divestiture. Medtronic Spin-Off MiniMed Files for IPO
• Neutral Sentiment: Analyst stances remain cautious: some firms (e.g., Robert W. Baird) are maintaining “hold” ratings, reflecting mixed near-term views even as the strategic move unfolds. Robert W. Baird Remains a Hold on Medtronic (MDT)
• Negative Sentiment: Price-target trim: Truist cut its MDT price target modestly (from $110 to $107) and kept a “hold” rating, a sign some analysts see limited near-term upside despite the strategic separation. This analyst action could cap momentum until clearer financials for MiniMed and separation mechanics are disclosed. Medtronic price target lowered to $107 from $110 at Truist

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).